Topics:

Anna Azvolinsky, PhD

Anna Azvolinsky, PhD

Freelance science writer and frequent Cancer Network and OncoTherapy Network contributor.

Follow Her on Twitter

Posts by Author

Metformin, a common drug for type II diabetes, did not improve the survival of patients with pancreatic ductal adenocarcinoma.

This slide show features some of the top highlights from the 2015 American Association for Cancer Research (AACR) Annual Meeting.

A multi-gene panel test provides better diagnostic yield compared with a limited BRCA1/2 genetic test for patients at risk for hereditary breast cancer.

The HPV 16/18 vaccine protects women from cervical, anal, and oral HPV infections that can lead to cancer, including some women previously exposed to HPV.

Combination treatment with the PARP inhibitor olaparib plus the PI3K inhibitor BKM120 showed a benefit in subsets of breast cancer and ovarian cancer patients.

Men with metastatic castration-resistant prostate cancer that had mutations in DNA repair genes were more likely to respond to the PARP inhibitor olaparib.

Women who spend less time eating each day and an increased amount of hours fasting overnight had a decreased risk of breast cancer.

In an ongoing study, the immunotherapy MPDL3280A continues to be well-tolerated and to show signs of activity in triple-negative breast cancer patients.

Too many people are being screened, diagnosed, and treated for certain types of cancer, according to two cancer researchers.

An MRI screening program for individuals at high risk for pancreatic cancer may be effective, according to the results of a short-term study.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.